Is GKOS a Buy or a Sell? The Bull and Bear Case (2026)

Last updated October 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Glaukos Corporation (GKOS) rests on iDose TR ramp: The iDose TR sustained-release glaucoma implant is the single biggest growth driver, contributing around $54 million in Q1 2026 and powering the US glaucoma franchise up roughly 58% year over year. The bear case rests on glaukos is still unprofitable and trades at about 16 times trailing sales and more than 300 times forward earnings, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply. Analysts covering it publish targets from $172.00 to $225.00 against a $164.84 price, so even the professionals disagree by 27% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

Glaukos Corporation is a San Clemente, California ophthalmic medical technology and pharmaceutical company focused on glaucoma, corneal disorders, and retinal disease. It pioneered Micro-Invasive Glaucoma Surgery (MIGS) with the iStent family of implants and has expanded into sustained-release drug delivery with iDose TR (a glaucoma implant) and corneal therapies including Photrexa and the newer Epioxa cross-linking treatment for keratoconus. In October 2026 it added a retinal program by licensing RO-104, a tri-specific biologic for retinal diseases, from RevOpsis Therapeutics. The company sells through eye surgeons and clinics in the US and internationally. Growth has been accelerating: Q1 2026 net sales were roughly $150.6 million, up about 41% year over year (iDose TR contributed around $54 million), and Q2 2026 net sales reached about $185.6 million, up roughly 50%, taking trailing twelve-month revenue to about $613 million. The investment picture is a classic growth-versus-profitability tradeoff. Revenue is compounding quickly, with analysts expecting about $692 million for full-year 2026, yet Glaukos is still reporting net losses (about $18.4 million, or $0.14 per share on an adjusted basis, in Q2 2026, narrower than the roughly $0.21 analysts expected) as it spends heavily on commercial launches and R&D. The trailing net loss of about $188 million is inflated by a roughly $134 million loss in Q4 2025. It held about $286 million in cash against roughly $108 million of debt at the end of June, and the stock trades near 16 times trailing sales with a negative P/E, so the valuation leans on continued rapid adoption of iDose TR and Epioxa. Walnut is not an investment adviser; this is descriptive context, not a recommendation.

The bull case: what would have to be true for $225.00

The most optimistic published target on GKOS is $225.00, +36.5% from the $164.84 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. iDose TR ramp

The iDose TR sustained-release glaucoma implant is the single biggest growth driver, contributing around $54 million in Q1 2026 and powering the US glaucoma franchise up roughly 58% year over year. Its adoption reflects a shift toward procedural, drug-eluting glaucoma care rather than daily eye drops. Continued reimbursement clarity and a growing base of peer-reviewed clinical evidence support the ramp. In October 2026 Glaukos reported that a Phase 4 randomized trial of iDose TR combined with cataract surgery met its primary efficacy endpoint, adding to the evidence base surgeons look at.

2. Corneal health and Epioxa

The corneal-health segment (Photrexa and the newer Epioxa incision-free cross-linking therapy for keratoconus) is a second growth engine. A CMS permanent J-code for Epioxa helps de-risk near-term reimbursement and access as the launch scales. This diversifies Glaukos beyond glaucoma devices into rare corneal disease. In October 2026 the company also released three-year Phase 3 extension data showing durable efficacy and a favorable safety profile for Epioxa.

3. International expansion

International glaucoma procedures are growing, aided by the European commercial launch of iStent Infinite following EU MDR certification. Overseas markets broaden the addressable base beyond the US. This gives Glaukos additional runway even as domestic MIGS competition intensifies.

4. Path toward profitability

Rapid top-line growth combined with about $286 million in cash (against roughly $108 million of debt) gives Glaukos room to invest through its launches. Gross margin is about 79%, and losses narrowed to roughly $0.14 per share in Q2 2026 from $0.18 in Q1. Analysts on average expect the company to reach a small profit in Q4 2026 and about $0.52 of EPS in 2027, so the open question is how quickly operating leverage turns the current net losses into sustained profit.

The bear case: what would have to be true for $172.00

The most pessimistic published target is $172.00, +4.3% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Glaukos Corporation is worth if the risks below bite instead of the drivers above.

Glaukos is still unprofitable and trades at about 16 times trailing sales and more than 300 times forward earnings, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply. Reimbursement complexity is a recurring watchpoint, including Medicaid Drug Rebate Program impacts that have muted Photrexa and general pricing pressure in glaucoma devices. Competition is intense from Alcon, Sight Sciences, AbbVie, Johnson & Johnson, and others across MIGS and glaucoma drug delivery, and a competitor supply recovery or new launch could erode share. The legacy iStent business has shown flattish trends outside iDose, and international markets face new competitive product trialing. Heavy spending relative to current earnings means execution and continued access to capital both matter. The shares have swung widely, from a 52-week low near $73 to a high near $192, and the new RO-104 retinal license adds early-stage development risk.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding GKOS already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on GKOS

13 analysts cover GKOS, with an average target of $199.31 (+20.9% against $164.84) and a split of 13 buy, 1 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the GKOS forecast and price target page.

How is GKOS valued? (as of October 2026)

Price

$164.84

Market cap

$9.72B

Forward P/E

314.38

Price / book

14.22

Beta

0.69

52-week range

$73.16 to $191.62

Snapshot for GKOS as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$613M
Q2 2026 net sales: ~$185.6M (up ~50% YoY)
2026 revenue (analyst consensus): ~$692M
Gross margin: ~79%
Net income (TTM): ~-$188M
P/S (trailing): ~16x (P/E not meaningful)
Market cap: ~$9.8B
Cash / debt: ~$286M / ~$108M

Glaukos combines roughly 50% revenue growth with ongoing net losses, so it screens as a high-multiple growth medtech rather than a value name, with a negative trailing P/E and a forward P/E above 300. After a roughly 94% one-year gain the stock sits below the average analyst target of about $199. Q3 2026 results are due October 28, 2026, with consensus near $168 million of revenue and a loss of about $0.09 per share.

How do you decide if GKOS is a buy?

Rather than asking whether GKOS is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold GKOS indirectly through an index or sector ETF before adding more.

What would change your mind on GKOS

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: iDose TR ramp stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: glaukos is still unprofitable and trades at about 16 times trailing sales and more than 300 times forward earnings, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the GKOS stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about GKOS against your real portfolio and see your actual exposure before deciding.

Investing in Glaukos Corporation with AI

Connect the broker you already use and ask Walnut's AI how GKOS fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does GKOS fit me?

FAQ

Is GKOS a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on iDose TR ramp, with revenue (ttm) at ~$613M. The bear case rests on glaukos is still unprofitable and trades at about 16 times trailing sales and more than 300 times forward earnings, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply. Analysts covering it are spread from $172.00 to $225.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell GKOS?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Glaukos is still unprofitable and trades at about 16 times trailing sales and more than 300 times forward earnings, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $172.00, +4.3% from the $164.84 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

What is the bull case for GKOS?

iDose TR ramp. The iDose TR sustained-release glaucoma implant is the single biggest growth driver, contributing around $54 million in Q1 2026 and powering the US glaucoma franchise up roughly 58% year over year. The most optimistic analyst target on GKOS is $225.00, +36.5% from the $164.84 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for GKOS?

What does Glaukos Corporation do?

Glaukos Corporation is a San Clemente, California ophthalmic medical technology and pharmaceutical company focused on glaucoma, corneal disorders, and retinal disease.

What would have to change for GKOS to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (iDose TR ramp) stalling in the reported numbers rather than in the narrative, the risk above (glaukos is still unprofitable and trades at about 16 times trailing sales and more than 300 times forward earnings, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Glaukos (GKOS) do?

Glaukos is an ophthalmic medical technology and pharmaceutical company. It develops and sells treatments for glaucoma, corneal disorders, and retinal disease, including the iStent surgical implants, the iDose TR drug-delivery implant, and corneal therapies Photrexa and Epioxa.

Is Glaukos profitable?

Not yet on a net-income basis. Glaukos reported a net loss of roughly $18.4 million in Q2 2026 (adjusted EPS of about -$0.14, better than the roughly -$0.21 expected) and about $188 million over the last twelve months, as it invests heavily in commercial launches and R&D. Analysts on average expect a first small quarterly profit in Q4 2026 (as of October 2026).

How fast is Glaukos growing?

Very fast for a medtech company. Q2 2026 net sales rose about 50% year over year to roughly $185.6 million, after about 41% growth in Q1. Trailing twelve-month revenue is about $613 million, and analysts expect about $692 million for full-year 2026 (as of October 2026).

Walnut is informational, not investment advice, and gives no verdict on GKOS. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.